University of Giessen Lung Center (UGLC)

'Big Science': Top funding for EU lung research project PULMOTENSION

PULMOTENSION aims to uncover underlying molecular pathways of PH, identify distinct targets for anti-remodelling therapy and test new treatment options in preclinical and clinical trials. The combined expertise in PULMOTENSION extends from gene mutation discovery to therapeutic regimen establishment.

SourceUniversity of Giessen Lung Center (UGLC)·DateFeb 10, 2006

First report of cancer drug Gleevec as new target therapy for pulmonary hypertension

Gleevec has been found to reverse lung vascular remodeling and pulmonary hypertension in experimental models. Larger clinical trials are planned to test its safety and effectiveness.

SourceUniversity of Giessen Lung Center (UGLC)·JournalNew England Journal of Medicine·DateSep 29, 2005